Key result
Elevated visfatin predicts cardiovascular events in metabolic syndrome and type 2 diabetes.
Why the study?
Several clinical studies have shown that serum visfatin may predict cardiovascular disease and events in patients with Metabolic Syndrome and Type 2 Diabetes Mellitus, but its role compared with commonly used biomarkers remains to be clarified.
Does visfatin predict cardiovascular complications in patients with metabolic syndrome and type 2 diabetes?
Does visfatin predict cardiovascular complications in patients with metabolic syndrome and type 2 diabetes?
Visfatin is a promising biomarker that is elevated in metabolic syndrome and type 2 diabetes and may predict cardiovascular complications, though further investigation is needed.
Visfatin may flag higher CV risk in metabolic syndrome and T2D; leaves open its value as a predictive biomarker pending prospective validation.
Vistafin is insulin-mimicking adipocytokine secreted from visceral adipose tissue, which plays an essential role in a number of biological processes affected glucose uptake regulation, inflammation, immunity, insulin resistance, vascular calcification, capillary tube formation, endothelial cell function and angiogenesis. Circulating level of visfatin exhibits to be a sufficiently increased in MetS and Type 2 Diabetes Mellitus (T2DM) patients compared with healthy individuals. Several clinical studies have shown that serum vitafin may predict Cardiovascular (CV) disease and CV events in MetS and T2DM patients. The review summarizes the various aspects of the role of vistafin as biomarker of MetS compared with commonly used biomarkers, i.e. adiponectin, leptin, resistin, apelin. In future more investigations are needed to better understand the role of vistafin in dysmetabolic-related disease and its ability to predict CV complications in these patient population
No takes yet. Share an insight, caveat, or question.
Alexander Е. Berezin (2016) conducted a review in Metabolic Syndrome and Type 2 Diabetes Mellitus. Visfatin vs. Commonly used biomarkers (adiponectin, leptin, resistin, apelin) was evaluated on Cardiovascular disease and events. Visfatin levels are increased in metabolic syndrome and type 2 diabetes and may serve as a biomarker to predict cardiovascular disease and events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: